AmericanHHM
Pentamed® - High performance packaging films for medical devices

Medtronic Diabetes Breaks Ground with World's First Approval for MiniMed™ 780G System Integrated with Simplera Sync™ Disposable Sensor

Monday, January 08, 2024

Medtronic plc, a global leader in healthcare technology, has obtained CE Mark approval for its revolutionary MiniMed™ 780G system featuring Simplera Sync™—an all-in-one disposable continuous glucose monitor (CGM). This innovative device eliminates the need for fingersticks or overtape, providing an improved user experience with a simplified two-step insertion process and a more compact size, reducing it by half compared to previous Medtronic sensors.*

The phased introduction of this product in the European market is scheduled to commence in the summer of 2024. The MiniMed™ 780G system, which is compatible with the Guardian™ 4 sensor, represents the pinnacle of Medtronic's insulin delivery systems. It autonomously adjusts and corrects† glucose levels every 5 minutes§ and incorporates distinctive features such as Meal Detection™‡ to address post-meal hyperglycemia. This feature proves beneficial when users forget to administer insulin or miscalculate carb intake. With a unique 7-day infusion set, the system includes one of the lowest glucose target settings (as low as 100 mg/dL) among automated insulin delivery systems. This "treat to target" approach closely mimics non-diabetic glucose levels.

Both the Simplera Sync™ sensor and the Guardian™ 4 sensor operate without necessitating fingersticks.** The responsive algorithm of the MiniMed™ 780G system supports individuals living with diabetes, assisting them even when they occasionally overlook bolus doses or carb counting. By taking on more management responsibilities, the system helps alleviate the mental burden associated with diabetes.

Indicated for ages 7 and above and compatible with iOS and Android, the MiniMed™ 780G system with Simplera Sync™ sensor provides advanced diabetes management capabilities. However, it's crucial to note that the Simplera Sync™ sensor is not FDA-approved and is limited to investigational use in the U.S. Designed to leverage Medtronic's advanced AID algorithm, the Simplera Sync™ sensor aligns with the look and feel of the Simplera™ CGM.

Medtronic Diabetes is committed to easing the challenges of diabetes through cutting-edge technology and continuous support. With a legacy of over 40 years in pioneering innovations, the company is dedicated to shaping the future of diabetes management by advancing CGM sensors, intelligent dosing systems, and harnessing the power of data science and AI—all while prioritizing an exceptional customer experience.

Source: prnewswire.com

 

 

 

Equinix accelerated medical research...Healthcare CEO & Executive Strategy SummitHealthcare CNO SummitHealthcare CMO SummitHealthcare CFO, Financial Strategy & Revenue Cycle SummitACO Leadership SummitThe Healthcare Patient Experience & Engagement Summit 2024Healthcare Innovation & Transformation Summit